Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug
Julie Guillermet‐Guibert(Centre National de la Recherche Scientifique), Corinne Bousquet(Centre National de la Recherche Scientifique), Dmitri Pchejetski(Centre National de la Recherche Scientifique), Christiane Susini(Inserm), Leyre Brizuela(Centre National de la Recherche Scientifique), Céline Guilbeau‐Frugier(Centre National de la Recherche Scientifique), Lise Davenne(Centre National de la Recherche Scientifique), Nathalie Saint‐Laurent(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Olivier Cuvillier(Centre National de la Recherche Scientifique)
Cited by 139
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284